Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious t...
Saved in:
| Published in | Blood Vol. 113; no. 8; pp. 1619 - 1630 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
19.02.2009
American Society of Hematology |
| Series | Review Article |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1. In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs. Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood. Herein, we synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML. |
|---|---|
| AbstractList | Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1. In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs. Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood. Herein, we synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML.Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1. In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs. Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood. Herein, we synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML. Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1. In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs. Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood. Herein, we synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML. Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1. In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs. Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood. Herein, we synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML. |
| Author | Cortes, Jorge Quintás-Cardama, Alfonso |
| Author_xml | – sequence: 1 givenname: Alfonso surname: Quintás-Cardama fullname: Quintás-Cardama, Alfonso email: aquintas@mdanderson.org organization: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston – sequence: 2 givenname: Jorge surname: Cortes fullname: Cortes, Jorge organization: Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18827185$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcFO3DAURa2Kqgy0f1ChrLpLeXZsJ2ZRCaHSIoHY0LXl2C_g1okHOxlpdvxD_5AvaaYzRYUFK0v2vec-v3tA9oY4ICEfKXymtGHHbYjRlQygKaEqKee1gjdkQQWbL4DBHlkAgCy5quk-Ocj5JwDlFRPvyD5tGlbTRizI6VUMaKdgUtH6GOLtuohd0dpUmjbQx4ffy5j96FdY2LsUB2-Lfo0helcEnH5h78178rYzIeOH3XlIfpx_vTn7Xl5ef7s4O70srWD1WDIDtXViHoapxjEFgrKuFbVRzjHsKsmttJY3qIwVXYWcgQEm61ZIlF0jq0PyZctdTm2PzuIwJhP0MvnepLWOxuvnL4O_07dxpSslmOBqBnzaAVK8nzCPuvfZYghmwDhlLaWqpKJiFh79n_QU8W9rs-BkK7Ap5pyw09aPZvRxE-yDpqA3Fem_FelNRRoqva1oNvMX5if-67bd93He8cpj0tl6HCw6n9CO2kX_OuAPEd2s1w |
| CitedBy_id | crossref_primary_10_1016_j_leukres_2009_07_012 crossref_primary_10_1073_pnas_1301838110 crossref_primary_10_1186_s12943_016_0574_7 crossref_primary_10_4103_ijh_ijh_89_24 crossref_primary_10_1016_j_bcp_2009_10_009 crossref_primary_10_1016_j_bioorg_2022_106071 crossref_primary_10_1016_j_jphs_2021_05_001 crossref_primary_10_1016_j_breast_2012_07_010 crossref_primary_10_1016_j_leukres_2021_106641 crossref_primary_10_1016_j_jbc_2021_101128 crossref_primary_10_1080_14728222_2024_2344695 crossref_primary_10_1038_onc_2012_246 crossref_primary_10_1039_C6RA21271A crossref_primary_10_1093_bioinformatics_bts059 crossref_primary_10_1021_acs_jmedchem_3c01629 crossref_primary_10_4103_0366_6999_199824 crossref_primary_10_3389_fonc_2019_00863 crossref_primary_10_1016_j_yexcr_2017_12_001 crossref_primary_10_1016_j_leukres_2021_106512 crossref_primary_10_3390_ijms22073458 crossref_primary_10_1007_s10637_017_0457_9 crossref_primary_10_3892_or_2022_8355 crossref_primary_10_1016_j_htct_2018_10_003 crossref_primary_10_3390_ijms22084265 crossref_primary_10_1007_s11899_019_00550_8 crossref_primary_10_1002_ijc_33903 crossref_primary_10_1002_cpt_2699 crossref_primary_10_1038_leusup_2012_21 crossref_primary_10_1074_jbc_M111_263913 crossref_primary_10_1097_MPH_0000000000000337 crossref_primary_10_1007_s00432_021_03569_8 crossref_primary_10_1038_leusup_2012_26 crossref_primary_10_4103_jcrt_jcrt_274_21 crossref_primary_10_1186_s13045_015_0128_2 crossref_primary_10_1016_j_rccan_2018_02_001 crossref_primary_10_18632_oncotarget_23283 crossref_primary_10_1089_scd_2018_0196 crossref_primary_10_3390_ijms20246106 crossref_primary_10_1134_S0006297924060099 crossref_primary_10_1371_journal_pone_0066755 crossref_primary_10_1586_17474086_2014_955008 crossref_primary_10_3892_or_2016_5226 crossref_primary_10_1016_j_canlet_2016_02_037 crossref_primary_10_1182_blood_2011_10_384651 crossref_primary_10_1080_10428194_2016_1235275 crossref_primary_10_1039_C8AN01094C crossref_primary_10_7554_eLife_84149 crossref_primary_10_1016_j_biopha_2023_116099 crossref_primary_10_1021_acs_chemrev_0c00383 crossref_primary_10_1111_ejh_13238 crossref_primary_10_1007_s12026_013_8432_9 crossref_primary_10_31857_S0320972524060099 crossref_primary_10_1111_cas_13284 crossref_primary_10_1080_10245332_2017_1302179 crossref_primary_10_1134_S0026893316060030 crossref_primary_10_1159_000490697 crossref_primary_10_3103_S0095452720010028 crossref_primary_10_1053_j_seminhematol_2010_06_004 crossref_primary_10_1182_blood_2014_01_547943 crossref_primary_10_1080_10428194_2020_1795160 crossref_primary_10_18632_oncotarget_4950 crossref_primary_10_3390_healthcare9050590 crossref_primary_10_1136_jim_2020_001563 crossref_primary_10_18632_oncotarget_25241 crossref_primary_10_1186_s12885_022_10094_5 crossref_primary_10_1182_blood_2009_07_229864 crossref_primary_10_1586_ehm_12_30 crossref_primary_10_4103_ijc_ijc_573_21 crossref_primary_10_1186_s43042_022_00248_2 crossref_primary_10_3389_fonc_2021_682859 crossref_primary_10_18632_oncotarget_1319 crossref_primary_10_1002_ajh_21380 crossref_primary_10_1002_cncr_25527 crossref_primary_10_1016_j_leukres_2014_12_008 crossref_primary_10_4155_cli_14_129 crossref_primary_10_1016_j_prp_2024_155161 crossref_primary_10_1002_ajh_24774 crossref_primary_10_3390_cells12131703 crossref_primary_10_1016_j_leukres_2020_106458 crossref_primary_10_5315_wjh_v6_i1_1 crossref_primary_10_1007_s10354_013_0239_8 crossref_primary_10_1007_s15004_013_0080_7 crossref_primary_10_1016_j_blre_2011_09_001 crossref_primary_10_1080_07391102_2019_1676824 crossref_primary_10_1371_journal_pone_0025139 crossref_primary_10_2174_1566523221666210217155233 crossref_primary_10_1016_j_compbiolchem_2018_09_006 crossref_primary_10_1111_jcmm_13755 crossref_primary_10_1021_jm301891t crossref_primary_10_3343_lmo_2015_5_2_101 crossref_primary_10_1038_nrc_2016_154 crossref_primary_10_3390_cancers5031086 crossref_primary_10_3109_10428194_2011_555890 crossref_primary_10_1016_j_leukres_2009_08_031 crossref_primary_10_1002_cbin_70007 crossref_primary_10_1111_ejh_12597 crossref_primary_10_3892_mmr_2012_1183 crossref_primary_10_1007_s11899_011_0079_9 crossref_primary_10_1038_onc_2015_72 crossref_primary_10_18632_oncotarget_1339 crossref_primary_10_1016_j_comtox_2021_100180 crossref_primary_10_3389_fphar_2020_00891 crossref_primary_10_1111_jcmm_12319 crossref_primary_10_3390_cells10113197 crossref_primary_10_3892_ijo_2014_2489 crossref_primary_10_1007_s13277_016_5413_3 crossref_primary_10_2217_ijh_12_2 crossref_primary_10_1016_j_cellsig_2011_03_021 crossref_primary_10_1080_14756366_2016_1250757 crossref_primary_10_1097_PPO_0000000000000165 crossref_primary_10_1007_s00432_013_1488_z crossref_primary_10_1002_pros_22787 crossref_primary_10_1007_s40266_013_0085_9 crossref_primary_10_3389_fphar_2021_749361 crossref_primary_10_1586_17474086_2013_835697 crossref_primary_10_1007_s40272_018_0319_8 crossref_primary_10_1021_ja311756u crossref_primary_10_3389_fmolb_2023_1094321 crossref_primary_10_2174_0118756298270515231010062046 crossref_primary_10_1080_10428194_2020_1856834 crossref_primary_10_1007_s00277_012_1421_6 crossref_primary_10_18632_oncotarget_15369 crossref_primary_10_1016_j_clml_2016_09_007 crossref_primary_10_1186_s12864_022_08339_5 crossref_primary_10_3892_or_2014_3098 crossref_primary_10_1016_j_jtbi_2017_08_023 crossref_primary_10_1038_s41598_024_54728_z crossref_primary_10_13005_bpj_1631 crossref_primary_10_1111_j_1440_1827_2011_02688_x crossref_primary_10_4081_hr_2011_s3_e3 crossref_primary_10_1002_cam4_1187 crossref_primary_10_2147_DDDT_S469331 crossref_primary_10_52711_0974_360X_2023_00848 crossref_primary_10_1159_000501948 crossref_primary_10_1016_j_electacta_2025_146006 crossref_primary_10_3390_cancers15174354 crossref_primary_10_1093_carcin_bgt070 crossref_primary_10_1097_PAT_0b013e32834a9da8 crossref_primary_10_1038_leu_2013_171 crossref_primary_10_1007_s00108_010_2791_2 crossref_primary_10_3390_cancers13174400 crossref_primary_10_1016_j_ejmech_2013_03_013 crossref_primary_10_1089_gtmb_2012_0272 crossref_primary_10_1186_s12885_021_09162_z crossref_primary_10_1038_s43018_023_00588_x crossref_primary_10_1182_blood_2009_02_204693 crossref_primary_10_5812_gct_131389 crossref_primary_10_1021_jm100395q crossref_primary_10_1002_cmdc_201500019 crossref_primary_10_1007_s12185_014_1531_0 crossref_primary_10_1016_j_molonc_2011_04_001 crossref_primary_10_1038_s41467_024_55407_3 crossref_primary_10_3390_cancers13020293 crossref_primary_10_1016_j_yapd_2023_04_002 crossref_primary_10_3389_fbioe_2022_930966 crossref_primary_10_1371_journal_pone_0057650 crossref_primary_10_3390_diagnostics11081502 crossref_primary_10_1111_ejh_13084 crossref_primary_10_1593_neo_09836 crossref_primary_10_3390_diagnostics14030303 crossref_primary_10_1093_annonc_mds228 crossref_primary_10_1007_s12032_012_0348_z crossref_primary_10_1016_j_ccr_2009_08_012 crossref_primary_10_1586_ehm_09_66 crossref_primary_10_1002_cncr_26621 crossref_primary_10_1111_cas_13442 crossref_primary_10_1371_journal_pone_0015525 crossref_primary_10_1016_j_leukres_2015_07_008 crossref_primary_10_1038_onc_2012_186 crossref_primary_10_1016_j_molonc_2013_08_006 crossref_primary_10_1177_03000605231156757 crossref_primary_10_1038_s43018_024_00817_x crossref_primary_10_1039_C6RA23443G crossref_primary_10_1158_1541_7786_MCR_10_0040 crossref_primary_10_1371_journal_pone_0068442 crossref_primary_10_1186_s12964_021_00752_9 crossref_primary_10_1177_2040620714537865 crossref_primary_10_3390_diagnostics12051051 crossref_primary_10_1016_j_taap_2020_115013 crossref_primary_10_1002_jcb_30624 crossref_primary_10_1016_j_bbrc_2015_06_020 crossref_primary_10_1038_s41388_020_01387_9 crossref_primary_10_1007_s11095_012_0758_9 crossref_primary_10_3390_cells10020445 crossref_primary_10_1016_j_cancergencyto_2010_05_012 crossref_primary_10_3390_ijms222212178 crossref_primary_10_3389_fonc_2019_00839 crossref_primary_10_1080_2314808X_2022_2082133 crossref_primary_10_1517_13543784_2010_499898 crossref_primary_10_1002_anie_201507634 crossref_primary_10_1177_17557380221096495 crossref_primary_10_3389_fonc_2019_00833 crossref_primary_10_1016_j_leukres_2024_107542 crossref_primary_10_53446_actamednicomedia_1338837 crossref_primary_10_1021_acsmedchemlett_7b00247 crossref_primary_10_3324_haematol_2022_280757 crossref_primary_10_1002_jcb_26257 crossref_primary_10_1007_s00432_011_1086_x crossref_primary_10_17650_1818_8346_2024_19_4_150_163 crossref_primary_10_4155_cli_11_40 crossref_primary_10_1517_14656566_2011_597741 crossref_primary_10_4103_njcp_njcp_755_22 crossref_primary_10_1007_s00204_015_1552_3 crossref_primary_10_1038_leu_2012_258 crossref_primary_10_1155_2012_671702 crossref_primary_10_1007_s13277_015_4118_3 crossref_primary_10_1007_s40265_021_01662_3 crossref_primary_10_1091_mbc_e14_06_1038 crossref_primary_10_1158_1078_0432_CCR_15_0393 crossref_primary_10_1016_j_bcp_2010_05_001 crossref_primary_10_1089_dna_2012_1798 crossref_primary_10_3892_ol_2016_4942 crossref_primary_10_1182_blood_2015_06_653006 crossref_primary_10_1186_1755_8794_5_37 crossref_primary_10_3389_fnagi_2016_00254 crossref_primary_10_1016_j_critrevonc_2012_03_005 crossref_primary_10_1016_j_beha_2009_10_001 crossref_primary_10_1158_1078_0432_CCR_17_0235 crossref_primary_10_3109_00498254_2016_1152418 crossref_primary_10_1007_s12026_012_8353_z crossref_primary_10_3892_ijmm_2012_1207 crossref_primary_10_1126_science_abg5601 crossref_primary_10_1038_leu_2013_151 crossref_primary_10_1093_bfgp_elv059 crossref_primary_10_1080_15384101_2016_1160976 crossref_primary_10_1016_j_ejps_2023_106678 crossref_primary_10_1016_j_clml_2011_10_003 crossref_primary_10_1007_s12032_023_02287_0 crossref_primary_10_1038_nchembio_1085 crossref_primary_10_1007_s40259_013_0082_x crossref_primary_10_1016_j_cancergencyto_2010_02_005 crossref_primary_10_1186_s12935_018_0507_1 crossref_primary_10_1096_fj_12_205112 crossref_primary_10_4236_jct_2013_43092 crossref_primary_10_1016_j_biopha_2012_11_004 crossref_primary_10_3390_molecules30051015 crossref_primary_10_1038_s41598_024_65404_7 crossref_primary_10_1016_j_cej_2023_147683 crossref_primary_10_3892_ol_2024_14557 crossref_primary_10_3389_fonc_2022_720845 crossref_primary_10_1371_journal_pone_0218444 crossref_primary_10_1021_jm1012819 crossref_primary_10_1016_j_gde_2012_01_005 crossref_primary_10_1016_j_blre_2024_101196 crossref_primary_10_1080_17843286_2017_1316005 crossref_primary_10_1016_j_bmc_2010_06_081 crossref_primary_10_3109_10428194_2014_918969 crossref_primary_10_1002_slct_202300095 crossref_primary_10_1371_journal_pcbi_1010760 crossref_primary_10_3390_genes11030263 crossref_primary_10_1155_2015_325026 crossref_primary_10_1016_j_compbiolchem_2010_06_003 crossref_primary_10_1038_leu_2011_380 crossref_primary_10_3724_SP_J_1008_2010_00653 crossref_primary_10_1371_journal_pone_0159114 crossref_primary_10_1007_s40291_016_0208_1 crossref_primary_10_1093_bioinformatics_btr310 crossref_primary_10_1200_JCO_2017_76_7228 crossref_primary_10_1186_s12920_021_00968_1 crossref_primary_10_1016_j_exphem_2021_11_002 crossref_primary_10_1016_j_yexmp_2012_01_007 crossref_primary_10_18632_oncotarget_2072 crossref_primary_10_1002_jbt_23150 crossref_primary_10_1002_jbm_a_36837 crossref_primary_10_4103_ijh_ijh_59_23 crossref_primary_10_1002_cncr_27568 crossref_primary_10_1172_JCI129209 crossref_primary_10_1182_blood_2012_12_475194 crossref_primary_10_1039_C8RA10096A crossref_primary_10_3816_CLML_2010_s_002 crossref_primary_10_1016_j_medj_2024_11_003 crossref_primary_10_2174_0118715206272359231121105713 crossref_primary_10_1016_j_anndiagpath_2015_12_004 crossref_primary_10_1007_s13258_024_01614_7 crossref_primary_10_4081_hr_2011_e3 crossref_primary_10_1007_s12288_018_0933_1 crossref_primary_10_1007_s42399_022_01248_4 crossref_primary_10_1016_j_genrep_2016_10_002 crossref_primary_10_1517_13543784_2011_632407 crossref_primary_10_3389_fonc_2019_00088 crossref_primary_10_1517_14656566_2012_725722 crossref_primary_10_1038_s41419_021_04209_2 crossref_primary_10_3109_10428194_2013_772607 crossref_primary_10_1016_j_bcmd_2016_05_007 crossref_primary_10_3892_etm_2016_3577 crossref_primary_10_3109_10428194_2012_681654 crossref_primary_10_1016_j_aca_2019_03_055 crossref_primary_10_3892_ol_2022_13242 crossref_primary_10_1016_j_exphem_2023_06_002 crossref_primary_10_1016_j_leukres_2015_10_014 crossref_primary_10_17650_1818_8346_2024_19_3_45_60 crossref_primary_10_2174_1871525720666220819123639 crossref_primary_10_17795_ijcp_3961 crossref_primary_10_3389_fonc_2020_591843 crossref_primary_10_1248_bpb_b21_00672 crossref_primary_10_1016_j_leukres_2012_10_001 crossref_primary_10_3109_10428190903470349 crossref_primary_10_1016_j_bioorg_2021_105344 crossref_primary_10_1038_leu_2009_142 crossref_primary_10_1182_blood_2009_07_232595 crossref_primary_10_1007_s11899_019_00549_1 crossref_primary_10_4236_health_2021_134036 crossref_primary_10_3390_ijms23126386 crossref_primary_10_1002_cncr_26280 crossref_primary_10_2146_ajhp130506 crossref_primary_10_1007_s13277_011_0222_1 crossref_primary_10_1080_10428194_2016_1265116 crossref_primary_10_1016_j_clml_2013_05_012 crossref_primary_10_1074_jbc_M110_118653 crossref_primary_10_1186_s13045_016_0359_x crossref_primary_10_1097_FPC_0b013e32833a6890 crossref_primary_10_1158_0008_5472_CAN_10_0258 crossref_primary_10_2217_imt_10_66 crossref_primary_10_1016_j_canlet_2012_05_032 crossref_primary_10_1016_j_bioorg_2023_106966 crossref_primary_10_1134_S1070428024010226 crossref_primary_10_5812_jjcmb_118718 crossref_primary_10_1007_s00262_011_1126_z crossref_primary_10_1063_1674_0068_30_cjcp1704066 crossref_primary_10_2217_bmm_2023_0575 crossref_primary_10_1016_j_leukres_2014_06_006 crossref_primary_10_21320_2500_2139_2025_18_1_10_20 crossref_primary_10_1038_srep06948 crossref_primary_10_1016_j_bioorg_2019_103361 crossref_primary_10_1080_01635581_2014_894099 crossref_primary_10_1182_blood_2016_11_749978 crossref_primary_10_24287_1726_1708_2022_21_1_156_172 crossref_primary_10_1371_journal_pcbi_1006266 crossref_primary_10_1158_0008_5472_CAN_10_4600 crossref_primary_10_2217_pme_12_86 crossref_primary_10_1016_j_clinthera_2012_01_009 crossref_primary_10_1158_1541_7786_MCR_10_0356 crossref_primary_10_1182_bloodadvances_2020002973 crossref_primary_10_1080_01635581_2011_538485 crossref_primary_10_1016_j_canlet_2023_216517 crossref_primary_10_3390_cancers14143300 crossref_primary_10_1038_aps_2011_192 crossref_primary_10_3109_10428194_2012_659734 crossref_primary_10_12936_tenrikiyo_15_34 crossref_primary_10_3390_pharmaceutics14061294 crossref_primary_10_1002_cncr_26147 crossref_primary_10_1371_journal_pone_0229104 crossref_primary_10_18632_oncotarget_13951 crossref_primary_10_5966_sctm_2012_0159 crossref_primary_10_1007_s12288_020_01264_1 crossref_primary_10_1007_s12254_016_0294_0 crossref_primary_10_1200_JCO_2009_25_0779 crossref_primary_10_1002_cncr_29240 crossref_primary_10_3390_cancers16020313 crossref_primary_10_1002_cyto_b_21091 crossref_primary_10_1016_j_medcli_2012_10_028 crossref_primary_10_1038_s41392_021_00572_w crossref_primary_10_1016_j_critrevonc_2022_103580 crossref_primary_10_3109_10428194_2011_647309 crossref_primary_10_3109_10428194_2013_850164 crossref_primary_10_4103_ijciis_ijciis_85_22 crossref_primary_10_3389_fmolb_2023_1105678 crossref_primary_10_1002_dc_21795 crossref_primary_10_1186_s12878_019_0139_2 crossref_primary_10_3390_cancers14133047 crossref_primary_10_1182_blood_2011_01_331009 crossref_primary_10_1194_jlr_M033985 crossref_primary_10_1182_blood_2011_09_381855 crossref_primary_10_18632_oncotarget_2340 crossref_primary_10_1007_s00216_021_03609_9 crossref_primary_10_1186_1476_4598_9_112 crossref_primary_10_3390_antiox8090402 crossref_primary_10_1038_nrclinonc_2009_112 crossref_primary_10_1016_j_clml_2011_12_004 crossref_primary_10_1038_s41419_021_04169_7 crossref_primary_10_1021_acs_jmedchem_8b01872 crossref_primary_10_1158_1078_0432_CCR_09_3314 crossref_primary_10_3390_pharmaceutics14010215 crossref_primary_10_1007_s00018_024_05379_w crossref_primary_10_1016_j_cmonc_2012_10_004 crossref_primary_10_1200_GO_22_00131 crossref_primary_10_1111_ijlh_12605 crossref_primary_10_1016_j_mcpro_2024_100778 crossref_primary_10_4155_fmc_2019_0161 crossref_primary_10_1016_j_ejmech_2019_05_091 crossref_primary_10_1038_onc_2011_604 crossref_primary_10_1186_s43042_023_00460_8 crossref_primary_10_1016_j_leukres_2013_07_026 crossref_primary_10_1002_ange_201507634 crossref_primary_10_1016_j_leukres_2010_01_025 crossref_primary_10_1016_j_leukres_2009_09_001 crossref_primary_10_1155_2014_596483 crossref_primary_10_1093_mmy_myy136 crossref_primary_10_1002_gcc_22046 crossref_primary_10_1002_cncr_26196 crossref_primary_10_1016_j_gendis_2025_101536 crossref_primary_10_1016_j_leukres_2014_08_015 crossref_primary_10_3892_ol_2013_1228 crossref_primary_10_1254_fpj_153_147 crossref_primary_10_1016_j_beha_2009_07_006 crossref_primary_10_1111_ijlh_12616 crossref_primary_10_1007_s12026_012_8369_4 crossref_primary_10_23736_S0392_0488_17_05818_7 crossref_primary_10_3390_biology10111182 crossref_primary_10_1016_j_neo_2019_06_001 crossref_primary_10_3390_cancers13040798 crossref_primary_10_1111_bjh_18983 crossref_primary_10_1517_14740331003742935 crossref_primary_10_3389_fcell_2021_825611 crossref_primary_10_3390_cancers14030620 crossref_primary_10_1016_j_arabjc_2021_103054 crossref_primary_10_1371_journal_pone_0028395 crossref_primary_10_1007_s11899_010_0045_y crossref_primary_10_1097_FPC_0b013e328351f3e9 crossref_primary_10_3109_10428190903383427 crossref_primary_10_4062_biomolther_2019_051 crossref_primary_10_1016_j_exphem_2021_05_006 crossref_primary_10_1182_blood_2011_01_328294 crossref_primary_10_1016_j_blre_2011_02_001 crossref_primary_10_1158_1078_0432_CCR_14_1186 crossref_primary_10_1134_S0026893321030043 crossref_primary_10_1007_s11684_014_0324_4 crossref_primary_10_3390_molecules30051065 crossref_primary_10_3390_ph17030349 crossref_primary_10_3389_fphar_2017_00802 crossref_primary_10_1016_j_cancergencyto_2009_09_018 crossref_primary_10_1080_13696998_2016_1225578 crossref_primary_10_1186_s12943_022_01707_5 crossref_primary_10_1111_ijlh_12919 crossref_primary_10_3390_hematolrep17010001 crossref_primary_10_1248_cpb_c18_00703 crossref_primary_10_1007_s12094_012_0926_8 crossref_primary_10_1016_j_bjhh_2014_07_006 crossref_primary_10_1039_C6IB00127K crossref_primary_10_1186_gm191 crossref_primary_10_4274_uob_galenos_2022_2022_4_1 crossref_primary_10_1007_s13277_014_1926_9 crossref_primary_10_1186_s12951_024_02505_5 crossref_primary_10_1007_s12288_021_01451_8 crossref_primary_10_1016_j_leukres_2012_12_003 crossref_primary_10_3109_10428194_2010_546913 crossref_primary_10_1039_C4MB00350K crossref_primary_10_1155_2020_7696204 crossref_primary_10_1016_j_ygeno_2013_06_004 crossref_primary_10_1038_srep24057 crossref_primary_10_1002_mc_22061 crossref_primary_10_2174_1574888X17666221003125208 crossref_primary_10_18632_oncotarget_2278 crossref_primary_10_1002_ijc_25367 crossref_primary_10_5009_gnl_2013_7_3_270 crossref_primary_10_2147_JBM_S382090 crossref_primary_10_1158_1078_0432_CCR_09_1068 crossref_primary_10_1097_PPO_0b013e31823dec8d crossref_primary_10_1016_j_gene_2017_09_036 crossref_primary_10_1016_j_taap_2019_114857 crossref_primary_10_7759_cureus_67412 crossref_primary_10_1007_s00216_024_05492_6 crossref_primary_10_1016_j_bcp_2018_05_018 crossref_primary_10_1016_j_leukres_2013_07_013 crossref_primary_10_1158_1078_0432_CCR_13_1999 crossref_primary_10_1016_j_jmoldx_2019_03_002 crossref_primary_10_18632_oncotarget_333 crossref_primary_10_1016_j_bioorg_2022_105848 crossref_primary_10_1007_s10822_012_9593_7 crossref_primary_10_1016_j_bmcl_2016_09_041 crossref_primary_10_1016_j_bulcan_2019_03_013 crossref_primary_10_1111_j_1349_7006_2009_01365_x crossref_primary_10_1039_c3mb70577c crossref_primary_10_14348_molcells_2016_2350 crossref_primary_10_3390_ijms242417600 crossref_primary_10_1038_s41392_022_01290_7 crossref_primary_10_1007_s12098_020_03234_x crossref_primary_10_3390_md20010026 crossref_primary_10_1155_2020_4956329 crossref_primary_10_7314_APJCP_2013_14_4_2447 crossref_primary_10_1080_21655979_2021_1957749 crossref_primary_10_1016_j_omtn_2017_05_003 crossref_primary_10_1186_s12943_021_01434_3 crossref_primary_10_1038_s41598_018_20179_6 crossref_primary_10_1016_j_bmcl_2013_05_095 crossref_primary_10_1016_j_bbrc_2021_03_162 crossref_primary_10_30621_jbachs_848797 |
| Cites_doi | 10.1073/pnas.0606509103 10.1182/blood-2002-12-3659 10.1126/science.289.5486.1938 10.1016/S0092-8674(03)00191-0 10.1056/NEJMoa052643 10.1074/jbc.271.49.31704 10.1182/blood.V96.6.2277 10.1038/nature03669 10.1016/S0092-8674(00)81348-3 10.1038/nm1274 10.1084/jem.20061444 10.1182/blood-2004-05-1941 10.1038/nrc2126 10.1182/blood.V101.2.690 10.1182/blood.V85.8.2013.bloodjournal8582013 10.1073/pnas.1633833100 10.1182/blood.V86.2.726.bloodjournal862726 10.1158/0008-5472.CAN-05-0076 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P 10.1021/jm049486a 10.1128/MCB.20.4.1149-1161.2000 10.1073/pnas.0602402103 10.1038/sj.leu.2403724 10.1182/blood-2005-05-2155 10.1016/S1470-2045(07)70342-X 10.1182/blood.V99.10.3530 10.1002/gcc.20487 10.1182/blood-2005-07-2947 10.1182/blood.V88.7.2375.bloodjournal8872375 10.1182/blood.V97.8.2406 10.1038/sj.onc.1208596 10.1084/jem.183.3.811 10.1182/blood-2004-06-2208 10.1038/nrc1567 10.1126/science.1099480 10.1038/sj.leu.2402741 10.1038/sj.onc.1206620 10.1016/S0092-8674(02)00623-2 10.1126/science.2406902 10.4065/81.7.973 10.1074/jbc.M111501200 10.1182/blood.V99.1.319 10.1038/385595a0 10.1016/S0092-8674(01)00188-X 10.1056/NEJM199907153410306 10.1093/jnci/djn188 10.1182/blood-2003-01-0123 10.1158/0008-5472.CAN-05-4187 10.1016/S1535-6108(02)00074-0 10.1182/blood-2006-11-057521 10.1073/pnas.0508143103 10.1016/j.ccr.2004.10.015 10.1172/JCI31095 10.1016/j.cell.2004.10.010 10.1200/JCO.2005.05.531 10.1038/385602a0 10.1016/j.stem.2007.08.009 10.1158/0008-5472.CAN-03-3656 10.1038/sj.leu.2404609 10.1182/blood.V99.10.3792 10.1016/S0092-8674(05)80094-7 10.1073/pnas.0504952102 10.1038/344251a0 10.1128/MCB.21.3.840-853.2001 10.1001/jama.294.11.1359 10.1182/blood.V86.6.2371.bloodjournal8662371 10.1182/blood-2005-09-3732 10.1182/blood-2003-12-4369 10.1038/ng1343 10.1182/blood-2002-09-2896 10.1073/pnas.0609239103 10.1128/MCB.02202-05 10.1158/0008-5472.CAN-03-1484 10.1073/pnas.0604716104 10.1038/sj.leu.2404227 10.1073/pnas.102583199 10.1093/emboj/17.15.4442 10.1038/sj.leu.2405086 10.1159/000046636 10.1038/ng791 10.1016/S0092-8674(03)00194-6 10.1016/S0092-8674(03)00190-9 10.1016/j.ccr.2005.01.007 10.1093/emboj/18.17.4754 10.1038/nrm1280 10.1182/blood-2007-03-080838 10.1016/S1470-2045(03)00979-3 10.1038/sj.leu.2403426 10.1038/sj.leu.2404318 10.1016/j.ccr.2007.10.015 10.1182/blood-2007-05-091769 10.1182/blood-2005-07-2815 10.1074/jbc.274.39.27956 10.1056/NEJMoa030847 10.1182/blood.V96.6.2269 10.1074/jbc.M402290200 10.1016/S1535-6108(02)00096-X 10.1074/jbc.M801337200 10.1038/nm1487 10.1056/NEJMoa055104 10.1016/j.dnarep.2005.10.005 10.1073/pnas.0510423103 10.1371/journal.pbio.0040144 10.1038/sj.onc.1202619 10.1016/j.hoc.2004.03.012 10.1016/j.ccr.2005.10.015 10.1182/blood-2004-08-3097 10.1182/blood.V88.7.2410.bloodjournal8872410 10.1038/nrc2147 10.1093/jnci/djk150 10.1016/S1097-2765(03)00274-0 10.1056/NEJMp038130 10.1038/sj.onc.1201490 10.1038/nature06866 10.1182/blood-2005-09-3596 10.1056/NEJMoa040258 10.1158/0008-5472.CAN-05-0259 10.1182/blood-2007-02-073031 10.1101/gad.1588607 10.1182/blood-2006-04-017400 10.1002/j.1460-2075.1994.tb06518.x 10.1126/science.1062538 10.1182/blood-2003-12-4111 10.1182/blood.V92.10.3829 10.1056/NEJM200104053441402 10.1038/sj.onc.1208796 10.1172/JCI30890 10.1056/NEJMoa055229 10.1084/jem.190.3.411 |
| ContentType | Journal Article |
| Copyright | 2009 © 2009 by The American Society of Hematology 2009 by The American Society of Hematology 2009 |
| Copyright_xml | – notice: 2009 © 2009 by The American Society of Hematology – notice: 2009 by The American Society of Hematology 2009 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1182/blood-2008-03-144790 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| EndPage | 1630 |
| ExternalDocumentID | PMC3952549 18827185 10_1182_blood_2008_03_144790 S0006497120376643 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 9M8 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFFNX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N4W N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ AALRI AAYXX ACVFH ADCNI ADVLN AEUPX AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP AMRAJ CITATION H13 CGR CUY CVF ECM EFKBS EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c527t-2a07cd5971298d290512fb57a9dd2ef364c6cc48e9ac5f3e420a0267b56e6f863 |
| ISSN | 0006-4971 1528-0020 |
| IngestDate | Thu Aug 21 13:25:31 EDT 2025 Thu Jul 10 22:39:48 EDT 2025 Mon Jul 21 05:58:57 EDT 2025 Tue Jul 01 04:18:06 EDT 2025 Thu Apr 24 22:51:32 EDT 2025 Fri Feb 23 02:45:32 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| License | This article is made available under the Elsevier license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c527t-2a07cd5971298d290512fb57a9dd2ef364c6cc48e9ac5f3e420a0267b56e6f863 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2008-03-144790 |
| PMID | 18827185 |
| PQID | 66936915 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3952549 proquest_miscellaneous_66936915 pubmed_primary_18827185 crossref_citationtrail_10_1182_blood_2008_03_144790 crossref_primary_10_1182_blood_2008_03_144790 elsevier_sciencedirect_doi_10_1182_blood_2008_03_144790 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2009-02-19 |
| PublicationDateYYYYMMDD | 2009-02-19 |
| PublicationDate_xml | – month: 02 year: 2009 text: 2009-02-19 day: 19 |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Washington, DC |
| PublicationSeriesTitle | Review Article |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2009 |
| Publisher | Elsevier Inc American Society of Hematology |
| Publisher_xml | – name: Elsevier Inc – name: American Society of Hematology |
| References | Guo, Wang, Arlinghaus (bib45) 1991; 51 Shah, Skaggs, Branford (bib137) 2007; 117 Donato, Wu, Stapley (bib51) 2003; 101 Gaiger, Henn, Horth (bib44) 1995; 86 Jamieson, Ailles, Dylla (bib48) 2004; 351 Ren (bib15) 2005; 5 Gesbert, Griffin (bib34) 2000; 96 Perrotti, Bonatti, Trotta (bib57) 1998; 17 Radich, Dai, Mao (bib89) 2006; 103 Cortes, Jabbour, Kantarjian (bib123) 2007; 110 Perrotti, Cesi, Trotta (bib59) 2002; 30 Zhang, Ren (bib7) 1998; 92 Calabretta, Perrotti (bib73) 2004; 103 Slupianek, Nowicki, Koptyra, Skorski (bib68) 2006; 5 Sicheri, Moarefi, Kuriyan (bib19) 1997; 385 Quintas-Cardama, Gibbons, Kantarjian (bib125) 2007; 110 Levinson, Kuchment, Shen (bib20) 2006; 4 Holtz, Forman, Bhatia (bib98) 2005; 19 Nagar, Hantschel, Young (bib17) 2003; 112 Sill, Goldman, Cross (bib78) 1995; 85 Neering, Bushnell, Sozer (bib97) 2007; 110 Skorski, Kanakaraj, Nieborowska-Skorska (bib27) 1995; 86 Thomas, Cancelas, Chae (bib37) 2007; 12 Cambier, Chopra, Strasser, Metcalf, Elefanty (bib47) 1998; 16 Kirstetter, Thomas, Dierich, Kastner, Chan (bib62) 2002; 32 Jiang, Zhao, Smith (bib49) 2007; 21 Kaneta, Kagami, Tsunoda, Ohno, Nakamura, Katagiri (bib86) 2003; 23 Konig, Holtz, Modi (bib105) 2008; 22 Quintás-Cardama, Cortes (bib1) 2006; 81 Jiang, Saw, Eaves, Eaves (bib106) 2007; 99 Faderl, Talpaz, Estrov, O'Brien, Kurzrock, Kantarjian (bib10) 1999; 341 Zheng, Li, Haak (bib88) 2006; 20 Hantschel, Superti-Furga (bib12) 2004; 5 Jamieson, Weissman, Passegue (bib93) 2004; 6 Xu, Harrison, Eck (bib18) 1997; 385 Yong, Szydlo, Goldman, Apperley, Melo (bib90) 2006; 107 Shah, Tran, Lee, Chen, Norris, Sawyers (bib122) 2004; 305 Nowicki, Falinski, Koptyra (bib66) 2004; 104 Graham, Jorgensen, Allan (bib100) 2002; 99 Holtz, Slovak, Zhang, Sawyers, Forman, Bhatia (bib99) 2002; 99 Nagar, Bornmann, Pellicena (bib118) 2002; 62 Koschmieder, Gottgens, Zhang (bib8) 2005; 105 Skaggs, Gorre, Ryvkin (bib135) 2006; 103 Smith, Yacobi, Van Etten (bib23) 2003; 12 Apperley (bib133) 2007; 8 Pluk, Dorey, Superti-Furga (bib21) 2002; 108 Sattler, Mohi, Pride (bib26) 2002; 1 Hu, Liu, Pelletier (bib54) 2004; 36 Gambacorti-Passerini, Gunby, Piazza, Galietta, Rostagno, Scapozza (bib113) 2003; 4 Kronenwett, Butterweck, Steidl (bib87) 2005; 24 Ilaria, Van Etten (bib29) 1996; 271 Branford, Rudzki, Walsh (bib130) 2003; 102 Dash, Williams, Kutok (bib63) 2002; 99 Barnes, Schultheis, Adedeji, Melo (bib46) 2005; 24 Angel, Karin (bib41) 1991; 1072 Druker, Sawyers, Kantarjian (bib2) 2001; 344 Kovitz, Kantarjian, Garcia-Manero, Abruzzo, Cortes (bib77) 2006; 108 Shah, Nicoll, Nagar (bib109) 2002; 2 Lombardo, Lee, Chen (bib121) 2004; 47 Griswold, MacPartlin, Bumm (bib136) 2006; 26 Dai, Rahmani, Corey, Dent, Grant (bib50) 2004; 279 Gabriele, Phung, Fukumoto (bib33) 1999; 190 Nosaka, Kawashima, Misawa, Ikuta, Mui, Kitamura (bib30) 1999; 18 Miething, Grundler, Mugler (bib81) 2007; 104 Sexl, Piekorz, Moriggl (bib31) 2000; 96 Soverini, Martinelli, Rosti (bib131) 2005; 23 Hoelbl, Kovacic, Kerenyi (bib32) 2006; 107 Tokarski, Newitt, Chang (bib116) 2006; 66 Wu, Meng, Kong (bib56) 2008; 100 Melo (bib9) 1996; 88 Mullighan, Miller, Radtke (bib61) 2008; 453 Talpaz, Shah, Kantarjian (bib120) 2006; 354 Deininger, Buchdunger, Druker (bib128) 2005; 105 Weisberg, Manley, Cowan-Jacob, Hochhaus, Griffin (bib134) 2007; 7 Vajpai, Strauss, Fendrich (bib117) 2008; 283 Huntly, Bench, Green (bib75) 2003; 102 Nucifora, Birn, Espinosa (bib64) 1993; 81 Hu, Swerdlow, Duffy, Weinmann, Lee, Li (bib55) 2006; 103 Hao, Ren (bib40) 2000; 20 Jabbour, Kantarjian, Jones (bib132) 2006; 20 Neviani, Santhanam, Trotta (bib82) 2005; 8 Holtschke, Lohler, Kanno (bib39) 1996; 87 Carter, Wodicka, Shah (bib129) 2005; 102 Huntly, Shigematsu, Deguchi (bib92) 2004; 6 Sawyers, Hochhaus, Feldman (bib74) 2002; 99 Weisberg, Manley, Breitenstein (bib115) 2005; 7 Barnes, Palaiologou, Panousopoulou (bib107) 2005; 65 Gorre, Mohammed, Ellwood (bib110) 2001; 293 Jaiswal, Traver, Miyamoto, Akashi, Lagasse, Weissman (bib95) 2003; 100 Sonoyama, Matsumura, Ezoe (bib35) 2002; 277 Kantarjian, Giles, Wunderle (bib119) 2006; 354 Michor, Hughes, Iwasa (bib102) 2005; 435 Tian, Zhan, Walker (bib96) 2003; 349 O'Hare, Walters, Stoffregen (bib127) 2005; 65 Heisterkamp, Jenster, ten Hoeve, Zovich, Pattengale, Groffen (bib5) 1990; 344 Cortes, O'Dwyer (bib71) 2004; 18 Middleton, Zukas, Rubinstein (bib38) 2006; 203 Weissman (bib94) 2005; 294 Hochhaus, Kreil, Corbin (bib126) 2002; 16 Corbin, La Rosee, Stoffregen, Druker, Deininger (bib112) 2003; 101 Nowicki, Pawlowski, Fischer, Hess, Pawlowski, Skorski (bib85) 2003; 22 Pane, Frigeri, Sindona (bib11) 1996; 88 Hochhaus, La Rosee (bib108) 2004; 18 Löwenberg (bib111) 2003; 349 Carlesso, Frank, Griffin (bib58) 1996; 183 Notari, Neviani, Santhanam (bib28) 2006; 107 Ban, Gao, Amin (bib53) 2008; 111 Kappos, Antel, Comi (bib83) 2006; 355 Neviani, Santhanam, Oaks (bib84) 2007; 117 Ramaraj, Singh, Niu (bib3) 2004; 64 Daley, Van Etten, Baltimore (bib6) 1990; 247 Koptyra, Falinski, Nowicki (bib69) 2006; 108 Melo, Barnes (bib67) 2007; 7 Hantschel, Nagar, Guettler (bib16) 2003; 112 Passegué, Wagner, Weissman (bib43) 2004; 119 Roeder, Horn, Glauche, Hochhaus, Mueller, Loeffler (bib101) 2006; 12 Schindler, Bornmann, Pellicena, Miller, Clarkson, Kuriyan (bib114) 2000; 289 Williams, den Besten, Sherr (bib79) 2007; 21 Wendel, de Stanchina, Cepero (bib80) 2006; 103 Azam, Latek, Daley (bib124) 2003; 112 Zhao, Jiang, Verfaillie (bib4) 2001; 97 Cancelas, Lee, Prabhakar, Stringer, Zheng, Williams (bib36) 2005; 11 Feller, Knudsen, Hanafusa (bib13) 1994; 13 Copland, Hamilton, Elrick (bib104) 2006; 107 Zhao, Ghaffari, Lodish, Malashkevich, Kim (bib22) 2002; 9 Quintas-Cardama, Kantarjian, Talpaz (bib76) 2005; 105 Zhang, Subrahmanyam, Wong, Gross, Ren (bib24) 2001; 21 Wu, Kwon, Rattis (bib65) 2007; 1 Johansson, Fioretos, Mitelman (bib72) 2002; 107 Canitrot, Lautier, Laurent (bib70) 1999; 18 Pendergast, Quilliam, Cripe (bib25) 1993; 75 Brazma, Grace, Howard (bib91) 2007; 46 Donato, Wu, Stapley (bib52) 2004; 64 Smith, Katz, Mayer (bib14) 1999; 274 Wagner, Zhang, Rosenbauer (bib60) 2006; 103 Passegué, Jochum, Schorpp-Kistner, Mohle-Steinlein, Wagner (bib42) 2001; 104 Jørgensen, Allan, Jordanides, Mountford, Holyoake (bib103) 2007; 109 Gabriele (2019111723410492300_B33) 1999; 190 Sonoyama (2019111723410492300_B35) 2002; 277 Johansson (2019111723410492300_B72) 2002; 107 Pane (2019111723410492300_B11) 1996; 88 Hao (2019111723410492300_B40) 2000; 20 Sattler (2019111723410492300_B26) 2002; 1 Passegué (2019111723410492300_B43) 2004; 119 Druker (2019111723410492300_B2) 2001; 344 Holtschke (2019111723410492300_B39) 1996; 87 Canitrot (2019111723410492300_B70) 1999; 18 Gambacorti-Passerini (2019111723410492300_B113) 2003; 4 Weisberg (2019111723410492300_B115) 2005; 7 Perrotti (2019111723410492300_B59) 2002; 30 Zhao (2019111723410492300_B4) 2001; 97 Neviani (2019111723410492300_B82) 2005; 8 Hantschel (2019111723410492300_B16) 2003; 112 Cortes (2019111723410492300_B123) 2007; 110 Quintas-Cardama (2019111723410492300_B76) 2005; 105 Mullighan (2019111723410492300_B61) 2008; 453 Huntly (2019111723410492300_B75) 2003; 102 Neviani (2019111723410492300_B84) 2007; 117 Griswold (2019111723410492300_B136) 2006; 26 Zheng (2019111723410492300_B88) 2006; 20 Jiang (2019111723410492300_B106) 2007; 99 Dai (2019111723410492300_B50) 2004; 279 Wu (2019111723410492300_B56) 2008; 100 Yong (2019111723410492300_B90) 2006; 107 Weissman (2019111723410492300_B94) 2005; 294 Hu (2019111723410492300_B55) 2006; 103 Sill (2019111723410492300_B78) 1995; 85 Talpaz (2019111723410492300_B120) 2006; 354 Angel (2019111723410492300_B41) 1991; 1072 Thomas (2019111723410492300_B37) 2007; 12 Nosaka (2019111723410492300_B30) 1999; 18 Kantarjian (2019111723410492300_B119) 2006; 354 Quintás-Cardama (2019111723410492300_B1) 2006; 81 Guo (2019111723410492300_B45) 1991; 51 Zhang (2019111723410492300_B24) 2001; 21 Nagar (2019111723410492300_B17) 2003; 112 Ilaria (2019111723410492300_B29) 1996; 271 Sicheri (2019111723410492300_B19) 1997; 385 Brazma (2019111723410492300_B91) 2007; 46 Donato (2019111723410492300_B52) 2004; 64 Holtz (2019111723410492300_B98) 2005; 19 Xu (2019111723410492300_B18) 1997; 385 Levinson (2019111723410492300_B20) 2006; 4 Hochhaus (2019111723410492300_B108) 2004; 18 Cortes (2019111723410492300_B71) 2004; 18 Quintas-Cardama (2019111723410492300_B125) 2007; 110 Smith (2019111723410492300_B14) 1999; 274 Azam (2019111723410492300_B124) 2003; 112 Feller (2019111723410492300_B13) 1994; 13 Zhao (2019111723410492300_B22) 2002; 9 Barnes (2019111723410492300_B107) 2005; 65 Hoelbl (2019111723410492300_B32) 2006; 107 Hu (2019111723410492300_B54) 2004; 36 Carlesso (2019111723410492300_B58) 1996; 183 Branford (2019111723410492300_B130) 2003; 102 Nowicki (2019111723410492300_B66) 2004; 104 Corbin (2019111723410492300_B112) 2003; 101 Wendel (2019111723410492300_B80) 2006; 103 Cancelas (2019111723410492300_B36) 2005; 11 Shah (2019111723410492300_B109) 2002; 2 Gesbert (2019111723410492300_B34) 2000; 96 Kovitz (2019111723410492300_B77) 2006; 108 Williams (2019111723410492300_B79) 2007; 21 Zhang (2019111723410492300_B7) 1998; 92 Notari (2019111723410492300_B28) 2006; 107 Passegué (2019111723410492300_B42) 2001; 104 Kirstetter (2019111723410492300_B62) 2002; 32 Apperley (2019111723410492300_B133) 2007; 8 Cambier (2019111723410492300_B47) 1998; 16 Wagner (2019111723410492300_B60) 2006; 103 Tian (2019111723410492300_B96) 2003; 349 Holtz (2019111723410492300_B99) 2002; 99 Dash (2019111723410492300_B63) 2002; 99 Jamieson (2019111723410492300_B93) 2004; 6 Faderl (2019111723410492300_B10) 1999; 341 Michor (2019111723410492300_B102) 2005; 435 Hochhaus (2019111723410492300_B126) 2002; 16 Konig (2019111723410492300_B105) 2008; 22 Jiang (2019111723410492300_B49) 2007; 21 Nucifora (2019111723410492300_B64) 1993; 81 Vajpai (2019111723410492300_B117) 2008; 283 Kappos (2019111723410492300_B83) 2006; 355 Carter (2019111723410492300_B129) 2005; 102 Skaggs (2019111723410492300_B135) 2006; 103 Smith (2019111723410492300_B23) 2003; 12 Koschmieder (2019111723410492300_B8) 2005; 105 Koptyra (2019111723410492300_B69) 2006; 108 Calabretta (2019111723410492300_B73) 2004; 103 Jabbour (2019111723410492300_B132) 2006; 20 Jamieson (2019111723410492300_B48) 2004; 351 Wu (2019111723410492300_B65) 2007; 1 Copland (2019111723410492300_B104) 2006; 107 Sexl (2019111723410492300_B31) 2000; 96 Kaneta (2019111723410492300_B86) 2003; 23 Huntly (2019111723410492300_B92) 2004; 6 Donato (2019111723410492300_B51) 2003; 101 Slupianek (2019111723410492300_B68) 2006; 5 Jaiswal (2019111723410492300_B95) 2003; 100 Ren (2019111723410492300_B15) 2005; 5 Barnes (2019111723410492300_B46) 2005; 24 Miething (2019111723410492300_B81) 2007; 104 Neering (2019111723410492300_B97) 2007; 110 Middleton (2019111723410492300_B38) 2006; 203 Radich (2019111723410492300_B89) 2006; 103 Roeder (2019111723410492300_B101) 2006; 12 Deininger (2019111723410492300_B128) 2005; 105 Ban (2019111723410492300_B53) 2008; 111 Sawyers (2019111723410492300_B74) 2002; 99 Kronenwett (2019111723410492300_B87) 2005; 24 Pendergast (2019111723410492300_B25) 1993; 75 Tokarski (2019111723410492300_B116) 2006; 66 Gaiger (2019111723410492300_B44) 1995; 86 Melo (2019111723410492300_B67) 2007; 7 Daley (2019111723410492300_B6) 1990; 247 Hantschel (2019111723410492300_B12) 2004; 5 Perrotti (2019111723410492300_B57) 1998; 17 Nowicki (2019111723410492300_B85) 2003; 22 O'Hare (2019111723410492300_B127) 2005; 65 Melo (2019111723410492300_B9) 1996; 88 Soverini (2019111723410492300_B131) 2005; 23 Pluk (2019111723410492300_B21) 2002; 108 Shah (2019111723410492300_B122) 2004; 305 Shah (2019111723410492300_B137) 2007; 117 Skorski (2019111723410492300_B27) 1995; 86 Weisberg (2019111723410492300_B134) 2007; 7 Heisterkamp (2019111723410492300_B5) 1990; 344 Gorre (2019111723410492300_B110) 2001; 293 Nagar (2019111723410492300_B118) 2002; 62 Jørgensen (2019111723410492300_B103) 2007; 109 Schindler (2019111723410492300_B114) 2000; 289 Löwenberg (2019111723410492300_B111) 2003; 349 Ramaraj (2019111723410492300_B3) 2004; 64 Graham (2019111723410492300_B100) 2002; 99 Lombardo (2019111723410492300_B121) 2004; 47 |
| References_xml | – volume: 96 start-page: 2269 year: 2000 end-page: 2276 ident: bib34 article-title: Bcr/Abl activates transcription of the Bcl-X gene through STAT5. publication-title: Blood – volume: 4 start-page: 75 year: 2003 end-page: 85 ident: bib113 article-title: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. publication-title: Lancet Oncol – volume: 277 start-page: 8076 year: 2002 end-page: 8082 ident: bib35 article-title: Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. publication-title: J Biol Chem – volume: 271 start-page: 31704 year: 1996 end-page: 31710 ident: bib29 article-title: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. publication-title: J Biol Chem – volume: 117 start-page: 2408 year: 2007 end-page: 2421 ident: bib84 article-title: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. publication-title: J Clin Invest – volume: 453 start-page: 110 year: 2008 end-page: 114 ident: bib61 article-title: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. publication-title: Nature – volume: 47 start-page: 6658 year: 2004 end-page: 6661 ident: bib121 article-title: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. publication-title: J Med Chem – volume: 385 start-page: 595 year: 1997 end-page: 602 ident: bib18 article-title: Three-dimensional structure of the tyrosine kinase c-Src. publication-title: Nature – volume: 289 start-page: 1938 year: 2000 end-page: 1942 ident: bib114 article-title: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. publication-title: Science – volume: 385 start-page: 602 year: 1997 end-page: 609 ident: bib19 article-title: Crystal structure of the Src family tyrosine kinase Hck. publication-title: Nature – volume: 65 start-page: 4500 year: 2005 end-page: 4505 ident: bib127 article-title: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. publication-title: Cancer Res – volume: 274 start-page: 27956 year: 1999 end-page: 27962 ident: bib14 article-title: Activation of the Abl tyrosine kinase in vivo by Src homology 3 domains from the Src homology 2/Src homology 3 adaptor Nck. publication-title: J Biol Chem – volume: 344 start-page: 251 year: 1990 end-page: 253 ident: bib5 article-title: Acute leukaemia in bcr/abl transgenic mice. publication-title: Nature – volume: 88 start-page: 2375 year: 1996 end-page: 2384 ident: bib9 article-title: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. publication-title: Blood – volume: 103 start-page: 16870 year: 2006 end-page: 16875 ident: bib55 article-title: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. publication-title: Proc Natl Acad Sci U S A – volume: 22 start-page: 3952 year: 2003 end-page: 3963 ident: bib85 article-title: Chronic myelogenous leukemia molecular signature. publication-title: Oncogene – volume: 20 start-page: 1028 year: 2006 end-page: 1034 ident: bib88 article-title: Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. publication-title: Leukemia – volume: 109 start-page: 4016 year: 2007 end-page: 4019 ident: bib103 article-title: Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. publication-title: Blood – volume: 293 start-page: 876 year: 2001 end-page: 880 ident: bib110 article-title: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. publication-title: Science – volume: 36 start-page: 453 year: 2004 end-page: 461 ident: bib54 article-title: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. publication-title: Nat Genet – volume: 17 start-page: 4442 year: 1998 end-page: 4455 ident: bib57 article-title: TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. publication-title: EMBO J – volume: 7 start-page: 129 year: 2005 end-page: 141 ident: bib115 article-title: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. publication-title: Cancer Cell – volume: 46 start-page: 1039 year: 2007 end-page: 1050 ident: bib91 article-title: Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. publication-title: Genes Chromosomes Cancer – volume: 100 start-page: 10002 year: 2003 end-page: 10007 ident: bib95 article-title: Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. publication-title: Proc Natl Acad Sci U S A – volume: 2 start-page: 117 year: 2002 end-page: 125 ident: bib109 article-title: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. publication-title: Cancer Cell – volume: 100 start-page: 926 year: 2008 end-page: 939 ident: bib56 article-title: Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. publication-title: J Natl Cancer Inst – volume: 21 start-page: 2283 year: 2007 end-page: 2287 ident: bib79 article-title: Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. publication-title: Genes Dev – volume: 87 start-page: 307 year: 1996 end-page: 317 ident: bib39 article-title: Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. publication-title: Cell – volume: 101 start-page: 690 year: 2003 end-page: 698 ident: bib51 article-title: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. publication-title: Blood – volume: 107 start-page: 4898 year: 2006 end-page: 4906 ident: bib32 article-title: Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. publication-title: Blood – volume: 183 start-page: 811 year: 1996 end-page: 820 ident: bib58 article-title: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. publication-title: J Exp Med – volume: 9 start-page: 117 year: 2002 end-page: 120 ident: bib22 article-title: Structure of the Bcr-Abl oncoprotein oligomerization domain. publication-title: Nat Struct Biol – volume: 22 start-page: 748 year: 2008 end-page: 755 ident: bib105 article-title: Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. publication-title: Leukemia – volume: 112 start-page: 845 year: 2003 end-page: 857 ident: bib16 article-title: A myristoyl/phosphotyrosine switch regulates c-Abl. publication-title: Cell – volume: 104 start-page: 21 year: 2001 end-page: 32 ident: bib42 article-title: Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. publication-title: Cell – volume: 247 start-page: 824 year: 1990 end-page: 830 ident: bib6 article-title: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. publication-title: Science – volume: 75 start-page: 175 year: 1993 end-page: 185 ident: bib25 article-title: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. publication-title: Cell – volume: 99 start-page: 3792 year: 2002 end-page: 3800 ident: bib99 article-title: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. publication-title: Blood – volume: 18 start-page: 671 year: 2004 end-page: 684 ident: bib71 article-title: Clonal evolution in chronic myelogenous leukemia. publication-title: Hematol Oncol Clin North Am – volume: 20 start-page: 1149 year: 2000 end-page: 1161 ident: bib40 article-title: Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. publication-title: Mol Cell Biol – volume: 341 start-page: 164 year: 1999 end-page: 172 ident: bib10 article-title: The biology of chronic myeloid leukemia. publication-title: N Engl J Med – volume: 99 start-page: 7622 year: 2002 end-page: 7627 ident: bib63 article-title: A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. publication-title: Proc Natl Acad Sci U S A – volume: 97 start-page: 2406 year: 2001 end-page: 2412 ident: bib4 article-title: A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. publication-title: Blood – volume: 30 start-page: 48 year: 2002 end-page: 58 ident: bib59 article-title: BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. publication-title: Nat Genet – volume: 64 start-page: 5322 year: 2004 end-page: 5331 ident: bib3 article-title: Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. publication-title: Cancer Res – volume: 104 start-page: 3746 year: 2004 end-page: 3753 ident: bib66 article-title: BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. publication-title: Blood – volume: 12 start-page: 27 year: 2003 end-page: 37 ident: bib23 article-title: Autoinhibition of Bcr-Abl through its SH3 domain. publication-title: Mol Cell – volume: 344 start-page: 1038 year: 2001 end-page: 1042 ident: bib2 article-title: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. publication-title: N Engl J Med – volume: 24 start-page: 6432 year: 2005 end-page: 6440 ident: bib46 article-title: Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. publication-title: Oncogene – volume: 112 start-page: 859 year: 2003 end-page: 871 ident: bib17 article-title: Structural basis for the autoinhibition of c-Abl tyrosine kinase. publication-title: Cell – volume: 355 start-page: 1124 year: 2006 end-page: 1140 ident: bib83 article-title: Oral fingolimod (FTY720) for relapsing multiple sclerosis. publication-title: N Engl J Med – volume: 5 start-page: 243 year: 2006 end-page: 250 ident: bib68 article-title: BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. publication-title: DNA Repair – volume: 64 start-page: 672 year: 2004 end-page: 677 ident: bib52 article-title: Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. publication-title: Cancer Res – volume: 86 start-page: 2371 year: 1995 end-page: 2378 ident: bib44 article-title: Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. publication-title: Blood – volume: 18 start-page: 1321 year: 2004 end-page: 1331 ident: bib108 article-title: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. publication-title: Leukemia – volume: 110 start-page: 4005 year: 2007 end-page: 4011 ident: bib123 article-title: Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. publication-title: Blood – volume: 108 start-page: 247 year: 2002 end-page: 259 ident: bib21 article-title: Autoinhibition of c-Abl. publication-title: Cell – volume: 104 start-page: 4594 year: 2007 end-page: 4599 ident: bib81 article-title: Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. publication-title: Proc Natl Acad Sci U S A – volume: 351 start-page: 657 year: 2004 end-page: 667 ident: bib48 article-title: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. publication-title: N Engl J Med – volume: 16 start-page: 335 year: 1998 end-page: 348 ident: bib47 article-title: BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. publication-title: Oncogene – volume: 20 start-page: 1767 year: 2006 end-page: 1773 ident: bib132 article-title: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. publication-title: Leukemia – volume: 4 start-page: e144 year: 2006 ident: bib20 article-title: A Src-like inactive conformation in the abl tyrosine kinase domain. publication-title: PLoS Biol – volume: 305 start-page: 399 year: 2004 end-page: 401 ident: bib122 article-title: Overriding imatinib resistance with a novel ABL kinase inhibitor. publication-title: Science – volume: 12 start-page: 467 year: 2007 end-page: 478 ident: bib37 article-title: Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. publication-title: Cancer Cell – volume: 103 start-page: 4010 year: 2004 end-page: 4022 ident: bib73 article-title: The biology of CML blast crisis. publication-title: Blood – volume: 203 start-page: 2529 year: 2006 end-page: 2540 ident: bib38 article-title: Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. publication-title: J Exp Med – volume: 6 start-page: 587 year: 2004 end-page: 596 ident: bib92 article-title: MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. publication-title: Cancer Cell – volume: 105 start-page: 2640 year: 2005 end-page: 2653 ident: bib128 article-title: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. publication-title: Blood – volume: 117 start-page: 2562 year: 2007 end-page: 2569 ident: bib137 article-title: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. publication-title: J Clin Invest – volume: 102 start-page: 1160 year: 2003 end-page: 1168 ident: bib75 article-title: Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. publication-title: Blood – volume: 85 start-page: 2013 year: 1995 end-page: 2016 ident: bib78 article-title: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. publication-title: Blood – volume: 1 start-page: 541 year: 2007 end-page: 554 ident: bib65 article-title: Imaging hematopoietic precursor division in real time. publication-title: Cell Stem Cell – volume: 19 start-page: 1034 year: 2005 end-page: 1041 ident: bib98 article-title: Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. publication-title: Leukemia – volume: 294 start-page: 1359 year: 2005 end-page: 1366 ident: bib94 article-title: Stem cell research: paths to cancer therapies and regenerative medicine. publication-title: JAMA – volume: 81 start-page: 973 year: 2006 end-page: 988 ident: bib1 article-title: Chronic myeloid leukemia: diagnosis and treatment. publication-title: Mayo Clin Proc – volume: 18 start-page: 2676 year: 1999 end-page: 2680 ident: bib70 article-title: Mutator phenotype of BCR–ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. publication-title: Oncogene – volume: 108 start-page: 319 year: 2006 end-page: 327 ident: bib69 article-title: BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. publication-title: Blood – volume: 1072 start-page: 129 year: 1991 end-page: 157 ident: bib41 article-title: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. publication-title: Biochim Biophys Acta – volume: 88 start-page: 2410 year: 1996 end-page: 2414 ident: bib11 article-title: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). publication-title: Blood – volume: 107 start-page: 76 year: 2002 end-page: 94 ident: bib72 article-title: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. publication-title: Acta Haematol – volume: 107 start-page: 205 year: 2006 end-page: 212 ident: bib90 article-title: Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. publication-title: Blood – volume: 92 start-page: 3829 year: 1998 end-page: 3840 ident: bib7 article-title: Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. publication-title: Blood – volume: 16 start-page: 2190 year: 2002 end-page: 2196 ident: bib126 article-title: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. publication-title: Leukemia – volume: 7 start-page: 345 year: 2007 end-page: 356 ident: bib134 article-title: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. publication-title: Nat Rev Cancer – volume: 81 start-page: 2728 year: 1993 end-page: 2734 ident: bib64 article-title: Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. publication-title: Blood – volume: 99 start-page: 680 year: 2007 end-page: 693 ident: bib106 article-title: Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. publication-title: J Natl Cancer Inst – volume: 62 start-page: 4236 year: 2002 end-page: 4243 ident: bib118 article-title: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). publication-title: Cancer Res – volume: 279 start-page: 34227 year: 2004 end-page: 34239 ident: bib50 article-title: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. publication-title: J Biol Chem – volume: 66 start-page: 5790 year: 2006 end-page: 5797 ident: bib116 article-title: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. publication-title: Cancer Res – volume: 6 start-page: 531 year: 2004 end-page: 533 ident: bib93 article-title: Chronic versus acute myelogenous leukemia: a question of self-renewal. publication-title: Cancer Cell – volume: 23 start-page: 681 year: 2003 end-page: 691 ident: bib86 article-title: Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. publication-title: Int J Oncol – volume: 11 start-page: 886 year: 2005 end-page: 891 ident: bib36 article-title: Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. publication-title: Nat Med – volume: 102 start-page: 276 year: 2003 end-page: 283 ident: bib130 article-title: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. publication-title: Blood – volume: 103 start-page: 7444 year: 2006 end-page: 7449 ident: bib80 article-title: Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. publication-title: Proc Natl Acad Sci U S A – volume: 354 start-page: 2531 year: 2006 end-page: 2541 ident: bib120 article-title: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. publication-title: N Engl J Med – volume: 8 start-page: 1018 year: 2007 end-page: 1029 ident: bib133 article-title: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. publication-title: Lancet Oncol – volume: 108 start-page: 2811 year: 2006 end-page: 2813 ident: bib77 article-title: Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. publication-title: Blood – volume: 435 start-page: 1267 year: 2005 end-page: 1270 ident: bib102 article-title: Dynamics of chronic myeloid leukaemia. publication-title: Nature – volume: 283 start-page: 18292 year: 2008 end-page: 18302 ident: bib117 article-title: Solution conformations and dynamics of Abl kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. publication-title: J Biol Chem – volume: 23 start-page: 4100 year: 2005 end-page: 4109 ident: bib131 article-title: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. publication-title: J Clin Oncol – volume: 349 start-page: 1399 year: 2003 end-page: 1401 ident: bib111 article-title: Minimal residual disease in chronic myeloid leukemia. publication-title: N Engl J Med – volume: 12 start-page: 1181 year: 2006 end-page: 1184 ident: bib101 article-title: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. publication-title: Nat Med – volume: 1 start-page: 479 year: 2002 end-page: 492 ident: bib26 article-title: Critical role for Gab2 in transformation by BCR/ABL. publication-title: Cancer Cell – volume: 13 start-page: 2341 year: 1994 end-page: 2351 ident: bib13 article-title: c-Abl kinase regulates the protein binding activity of c-Crk. publication-title: EMBO J – volume: 190 start-page: 411 year: 1999 end-page: 421 ident: bib33 article-title: Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. publication-title: J Exp Med – volume: 105 start-page: 2281 year: 2005 end-page: 2286 ident: bib76 article-title: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. publication-title: Blood – volume: 65 start-page: 8912 year: 2005 end-page: 8919 ident: bib107 article-title: Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. publication-title: Cancer Res – volume: 349 start-page: 2483 year: 2003 end-page: 2494 ident: bib96 article-title: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. publication-title: N Engl J Med – volume: 7 start-page: 441 year: 2007 end-page: 453 ident: bib67 article-title: Chronic myeloid leukaemia as a model of disease evolution in human cancer. publication-title: Nat Rev Cancer – volume: 32 start-page: 720 year: 2002 end-page: 730 ident: bib62 article-title: Ikaros is critical for B cell differentiation and function. publication-title: Eur J Immunol – volume: 103 start-page: 19466 year: 2006 end-page: 19471 ident: bib135 article-title: Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. publication-title: Proc Natl Acad Sci U S A – volume: 96 start-page: 2277 year: 2000 end-page: 2283 ident: bib31 article-title: Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. publication-title: Blood – volume: 18 start-page: 4754 year: 1999 end-page: 4765 ident: bib30 article-title: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. publication-title: EMBO J – volume: 105 start-page: 324 year: 2005 end-page: 334 ident: bib8 article-title: Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. publication-title: Blood – volume: 21 start-page: 926 year: 2007 end-page: 935 ident: bib49 article-title: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. publication-title: Leukemia – volume: 26 start-page: 6082 year: 2006 end-page: 6093 ident: bib136 article-title: Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. publication-title: Mol Cell Biol – volume: 5 start-page: 172 year: 2005 end-page: 183 ident: bib15 article-title: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. publication-title: Nat Rev Cancer – volume: 86 start-page: 726 year: 1995 end-page: 736 ident: bib27 article-title: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. publication-title: Blood – volume: 51 start-page: 3048 year: 1991 end-page: 3051 ident: bib45 article-title: Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. publication-title: Cancer Res – volume: 107 start-page: 4532 year: 2006 end-page: 4539 ident: bib104 article-title: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. publication-title: Blood – volume: 103 start-page: 6338 year: 2006 end-page: 6343 ident: bib60 article-title: Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. publication-title: Proc Natl Acad Sci U S A – volume: 21 start-page: 840 year: 2001 end-page: 853 ident: bib24 article-title: The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. publication-title: Mol Cell Biol – volume: 354 start-page: 2542 year: 2006 end-page: 2551 ident: bib119 article-title: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. publication-title: N Engl J Med – volume: 111 start-page: 2904 year: 2008 end-page: 2908 ident: bib53 article-title: BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. publication-title: Blood – volume: 8 start-page: 355 year: 2005 end-page: 368 ident: bib82 article-title: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. publication-title: Cancer Cell – volume: 112 start-page: 831 year: 2003 end-page: 843 ident: bib124 article-title: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. publication-title: Cell – volume: 110 start-page: 2578 year: 2007 end-page: 2585 ident: bib97 article-title: Leukemia stem cells in a genetically defined murine model of blast-crisis CML. publication-title: Blood – volume: 107 start-page: 2507 year: 2006 end-page: 2516 ident: bib28 article-title: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. publication-title: Blood – volume: 99 start-page: 3530 year: 2002 end-page: 3539 ident: bib74 article-title: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. publication-title: Blood – volume: 101 start-page: 4611 year: 2003 end-page: 4614 ident: bib112 article-title: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. publication-title: Blood – volume: 102 start-page: 11011 year: 2005 end-page: 11016 ident: bib129 article-title: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. publication-title: Proc Natl Acad Sci U S A – volume: 24 start-page: 5313 year: 2005 end-page: 5324 ident: bib87 article-title: Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. publication-title: Oncogene – volume: 103 start-page: 2794 year: 2006 end-page: 2799 ident: bib89 article-title: Gene expression changes associated with progression and response in chronic myeloid leukemia. publication-title: Proc Natl Acad Sci U S A – volume: 5 start-page: 33 year: 2004 end-page: 44 ident: bib12 article-title: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. publication-title: Nat Rev Mol Cell Biol – volume: 99 start-page: 319 year: 2002 end-page: 325 ident: bib100 article-title: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. publication-title: Blood – volume: 110 start-page: 1938 year: 2007 ident: bib125 article-title: Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy. publication-title: Blood (ASH Annual Meeting Abstracts) – volume: 119 start-page: 431 year: 2004 end-page: 443 ident: bib43 article-title: JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. publication-title: Cell – volume: 103 start-page: 16870 year: 2006 ident: 2019111723410492300_B55 article-title: Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0606509103 – volume: 101 start-page: 4611 year: 2003 ident: 2019111723410492300_B112 article-title: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. publication-title: Blood doi: 10.1182/blood-2002-12-3659 – volume: 289 start-page: 1938 year: 2000 ident: 2019111723410492300_B114 article-title: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. publication-title: Science doi: 10.1126/science.289.5486.1938 – volume: 112 start-page: 845 year: 2003 ident: 2019111723410492300_B16 article-title: A myristoyl/phosphotyrosine switch regulates c-Abl. publication-title: Cell doi: 10.1016/S0092-8674(03)00191-0 – volume: 355 start-page: 1124 year: 2006 ident: 2019111723410492300_B83 article-title: Oral fingolimod (FTY720) for relapsing multiple sclerosis. publication-title: N Engl J Med doi: 10.1056/NEJMoa052643 – volume: 271 start-page: 31704 year: 1996 ident: 2019111723410492300_B29 article-title: P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. publication-title: J Biol Chem doi: 10.1074/jbc.271.49.31704 – volume: 96 start-page: 2277 year: 2000 ident: 2019111723410492300_B31 article-title: Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. publication-title: Blood doi: 10.1182/blood.V96.6.2277 – volume: 435 start-page: 1267 year: 2005 ident: 2019111723410492300_B102 article-title: Dynamics of chronic myeloid leukaemia. publication-title: Nature doi: 10.1038/nature03669 – volume: 87 start-page: 307 year: 1996 ident: 2019111723410492300_B39 article-title: Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. publication-title: Cell doi: 10.1016/S0092-8674(00)81348-3 – volume: 11 start-page: 886 year: 2005 ident: 2019111723410492300_B36 article-title: Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization. publication-title: Nat Med doi: 10.1038/nm1274 – volume: 203 start-page: 2529 year: 2006 ident: 2019111723410492300_B38 article-title: Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. publication-title: J Exp Med doi: 10.1084/jem.20061444 – volume: 104 start-page: 3746 year: 2004 ident: 2019111723410492300_B66 article-title: BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. publication-title: Blood doi: 10.1182/blood-2004-05-1941 – volume: 7 start-page: 345 year: 2007 ident: 2019111723410492300_B134 article-title: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. publication-title: Nat Rev Cancer doi: 10.1038/nrc2126 – volume: 101 start-page: 690 year: 2003 ident: 2019111723410492300_B51 article-title: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. publication-title: Blood doi: 10.1182/blood.V101.2.690 – volume: 85 start-page: 2013 year: 1995 ident: 2019111723410492300_B78 article-title: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. publication-title: Blood doi: 10.1182/blood.V85.8.2013.bloodjournal8582013 – volume: 100 start-page: 10002 year: 2003 ident: 2019111723410492300_B95 article-title: Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1633833100 – volume: 6 start-page: 531 year: 2004 ident: 2019111723410492300_B93 article-title: Chronic versus acute myelogenous leukemia: a question of self-renewal. publication-title: Cancer Cell – volume: 86 start-page: 726 year: 1995 ident: 2019111723410492300_B27 article-title: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. publication-title: Blood doi: 10.1182/blood.V86.2.726.bloodjournal862726 – volume: 65 start-page: 8912 year: 2005 ident: 2019111723410492300_B107 article-title: Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0076 – volume: 81 start-page: 2728 year: 1993 ident: 2019111723410492300_B64 article-title: Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. publication-title: Blood – volume: 32 start-page: 720 year: 2002 ident: 2019111723410492300_B62 article-title: Ikaros is critical for B cell differentiation and function. publication-title: Eur J Immunol doi: 10.1002/1521-4141(200203)32:3<720::AID-IMMU720>3.0.CO;2-P – volume: 47 start-page: 6658 year: 2004 ident: 2019111723410492300_B121 article-title: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. publication-title: J Med Chem doi: 10.1021/jm049486a – volume: 20 start-page: 1149 year: 2000 ident: 2019111723410492300_B40 article-title: Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. publication-title: Mol Cell Biol doi: 10.1128/MCB.20.4.1149-1161.2000 – volume: 103 start-page: 7444 year: 2006 ident: 2019111723410492300_B80 article-title: Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0602402103 – volume: 19 start-page: 1034 year: 2005 ident: 2019111723410492300_B98 article-title: Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. publication-title: Leukemia doi: 10.1038/sj.leu.2403724 – volume: 107 start-page: 205 year: 2006 ident: 2019111723410492300_B90 article-title: Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. publication-title: Blood doi: 10.1182/blood-2005-05-2155 – volume: 8 start-page: 1018 year: 2007 ident: 2019111723410492300_B133 article-title: Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. publication-title: Lancet Oncol doi: 10.1016/S1470-2045(07)70342-X – volume: 99 start-page: 3530 year: 2002 ident: 2019111723410492300_B74 article-title: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. publication-title: Blood doi: 10.1182/blood.V99.10.3530 – volume: 46 start-page: 1039 year: 2007 ident: 2019111723410492300_B91 article-title: Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. publication-title: Genes Chromosomes Cancer doi: 10.1002/gcc.20487 – volume: 107 start-page: 4532 year: 2006 ident: 2019111723410492300_B104 article-title: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. publication-title: Blood doi: 10.1182/blood-2005-07-2947 – volume: 88 start-page: 2375 year: 1996 ident: 2019111723410492300_B9 article-title: The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. publication-title: Blood doi: 10.1182/blood.V88.7.2375.bloodjournal8872375 – volume: 97 start-page: 2406 year: 2001 ident: 2019111723410492300_B4 article-title: A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. publication-title: Blood doi: 10.1182/blood.V97.8.2406 – volume: 24 start-page: 5313 year: 2005 ident: 2019111723410492300_B87 article-title: Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia. publication-title: Oncogene doi: 10.1038/sj.onc.1208596 – volume: 183 start-page: 811 year: 1996 ident: 2019111723410492300_B58 article-title: Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. publication-title: J Exp Med doi: 10.1084/jem.183.3.811 – volume: 105 start-page: 2281 year: 2005 ident: 2019111723410492300_B76 article-title: Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. publication-title: Blood doi: 10.1182/blood-2004-06-2208 – volume: 5 start-page: 172 year: 2005 ident: 2019111723410492300_B15 article-title: Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. publication-title: Nat Rev Cancer doi: 10.1038/nrc1567 – volume: 305 start-page: 399 year: 2004 ident: 2019111723410492300_B122 article-title: Overriding imatinib resistance with a novel ABL kinase inhibitor. publication-title: Science doi: 10.1126/science.1099480 – volume: 16 start-page: 2190 year: 2002 ident: 2019111723410492300_B126 article-title: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. publication-title: Leukemia doi: 10.1038/sj.leu.2402741 – volume: 22 start-page: 3952 year: 2003 ident: 2019111723410492300_B85 article-title: Chronic myelogenous leukemia molecular signature. publication-title: Oncogene doi: 10.1038/sj.onc.1206620 – volume: 108 start-page: 247 year: 2002 ident: 2019111723410492300_B21 article-title: Autoinhibition of c-Abl. publication-title: Cell doi: 10.1016/S0092-8674(02)00623-2 – volume: 247 start-page: 824 year: 1990 ident: 2019111723410492300_B6 article-title: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. publication-title: Science doi: 10.1126/science.2406902 – volume: 81 start-page: 973 year: 2006 ident: 2019111723410492300_B1 article-title: Chronic myeloid leukemia: diagnosis and treatment. publication-title: Mayo Clin Proc doi: 10.4065/81.7.973 – volume: 277 start-page: 8076 year: 2002 ident: 2019111723410492300_B35 article-title: Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR/ABL in K562 cells. publication-title: J Biol Chem doi: 10.1074/jbc.M111501200 – volume: 99 start-page: 319 year: 2002 ident: 2019111723410492300_B100 article-title: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. publication-title: Blood doi: 10.1182/blood.V99.1.319 – volume: 385 start-page: 595 year: 1997 ident: 2019111723410492300_B18 article-title: Three-dimensional structure of the tyrosine kinase c-Src. publication-title: Nature doi: 10.1038/385595a0 – volume: 104 start-page: 21 year: 2001 ident: 2019111723410492300_B42 article-title: Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage. publication-title: Cell doi: 10.1016/S0092-8674(01)00188-X – volume: 341 start-page: 164 year: 1999 ident: 2019111723410492300_B10 article-title: The biology of chronic myeloid leukemia. publication-title: N Engl J Med doi: 10.1056/NEJM199907153410306 – volume: 100 start-page: 926 year: 2008 ident: 2019111723410492300_B56 article-title: Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn188 – volume: 102 start-page: 1160 year: 2003 ident: 2019111723410492300_B75 article-title: Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. publication-title: Blood doi: 10.1182/blood-2003-01-0123 – volume: 66 start-page: 5790 year: 2006 ident: 2019111723410492300_B116 article-title: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4187 – volume: 1 start-page: 479 year: 2002 ident: 2019111723410492300_B26 article-title: Critical role for Gab2 in transformation by BCR/ABL. publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00074-0 – volume: 109 start-page: 4016 year: 2007 ident: 2019111723410492300_B103 article-title: Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. publication-title: Blood doi: 10.1182/blood-2006-11-057521 – volume: 103 start-page: 6338 year: 2006 ident: 2019111723410492300_B60 article-title: Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/abl-induced malignancy. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0508143103 – volume: 6 start-page: 587 year: 2004 ident: 2019111723410492300_B92 article-title: MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. publication-title: Cancer Cell doi: 10.1016/j.ccr.2004.10.015 – volume: 117 start-page: 2408 year: 2007 ident: 2019111723410492300_B84 article-title: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. publication-title: J Clin Invest doi: 10.1172/JCI31095 – volume: 119 start-page: 431 year: 2004 ident: 2019111723410492300_B43 article-title: JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. publication-title: Cell doi: 10.1016/j.cell.2004.10.010 – volume: 23 start-page: 4100 year: 2005 ident: 2019111723410492300_B131 article-title: ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.531 – volume: 385 start-page: 602 year: 1997 ident: 2019111723410492300_B19 article-title: Crystal structure of the Src family tyrosine kinase Hck. publication-title: Nature doi: 10.1038/385602a0 – volume: 1 start-page: 541 year: 2007 ident: 2019111723410492300_B65 article-title: Imaging hematopoietic precursor division in real time. publication-title: Cell Stem Cell doi: 10.1016/j.stem.2007.08.009 – volume: 110 start-page: 1938 year: 2007 ident: 2019111723410492300_B125 article-title: Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy. publication-title: Blood (ASH Annual Meeting Abstracts) – volume: 64 start-page: 5322 year: 2004 ident: 2019111723410492300_B3 article-title: Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-3656 – volume: 21 start-page: 926 year: 2007 ident: 2019111723410492300_B49 article-title: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. publication-title: Leukemia doi: 10.1038/sj.leu.2404609 – volume: 99 start-page: 3792 year: 2002 ident: 2019111723410492300_B99 article-title: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. publication-title: Blood doi: 10.1182/blood.V99.10.3792 – volume: 75 start-page: 175 year: 1993 ident: 2019111723410492300_B25 article-title: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. publication-title: Cell doi: 10.1016/S0092-8674(05)80094-7 – volume: 102 start-page: 11011 year: 2005 ident: 2019111723410492300_B129 article-title: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0504952102 – volume: 344 start-page: 251 year: 1990 ident: 2019111723410492300_B5 article-title: Acute leukaemia in bcr/abl transgenic mice. publication-title: Nature doi: 10.1038/344251a0 – volume: 21 start-page: 840 year: 2001 ident: 2019111723410492300_B24 article-title: The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. publication-title: Mol Cell Biol doi: 10.1128/MCB.21.3.840-853.2001 – volume: 294 start-page: 1359 year: 2005 ident: 2019111723410492300_B94 article-title: Stem cell research: paths to cancer therapies and regenerative medicine. publication-title: JAMA doi: 10.1001/jama.294.11.1359 – volume: 86 start-page: 2371 year: 1995 ident: 2019111723410492300_B44 article-title: Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. publication-title: Blood doi: 10.1182/blood.V86.6.2371.bloodjournal8662371 – volume: 107 start-page: 2507 year: 2006 ident: 2019111723410492300_B28 article-title: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. publication-title: Blood doi: 10.1182/blood-2005-09-3732 – volume: 105 start-page: 324 year: 2005 ident: 2019111723410492300_B8 article-title: Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. publication-title: Blood doi: 10.1182/blood-2003-12-4369 – volume: 36 start-page: 453 year: 2004 ident: 2019111723410492300_B54 article-title: Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. publication-title: Nat Genet doi: 10.1038/ng1343 – volume: 102 start-page: 276 year: 2003 ident: 2019111723410492300_B130 article-title: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. publication-title: Blood doi: 10.1182/blood-2002-09-2896 – volume: 103 start-page: 19466 year: 2006 ident: 2019111723410492300_B135 article-title: Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0609239103 – volume: 26 start-page: 6082 year: 2006 ident: 2019111723410492300_B136 article-title: Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. publication-title: Mol Cell Biol doi: 10.1128/MCB.02202-05 – volume: 64 start-page: 672 year: 2004 ident: 2019111723410492300_B52 article-title: Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-1484 – volume: 104 start-page: 4594 year: 2007 ident: 2019111723410492300_B81 article-title: Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0604716104 – volume: 20 start-page: 1028 year: 2006 ident: 2019111723410492300_B88 article-title: Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. publication-title: Leukemia doi: 10.1038/sj.leu.2404227 – volume: 99 start-page: 7622 year: 2002 ident: 2019111723410492300_B63 article-title: A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.102583199 – volume: 17 start-page: 4442 year: 1998 ident: 2019111723410492300_B57 article-title: TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. publication-title: EMBO J doi: 10.1093/emboj/17.15.4442 – volume: 22 start-page: 748 year: 2008 ident: 2019111723410492300_B105 article-title: Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. publication-title: Leukemia doi: 10.1038/sj.leu.2405086 – volume: 107 start-page: 76 year: 2002 ident: 2019111723410492300_B72 article-title: Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. publication-title: Acta Haematol doi: 10.1159/000046636 – volume: 30 start-page: 48 year: 2002 ident: 2019111723410492300_B59 article-title: BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. publication-title: Nat Genet doi: 10.1038/ng791 – volume: 112 start-page: 859 year: 2003 ident: 2019111723410492300_B17 article-title: Structural basis for the autoinhibition of c-Abl tyrosine kinase. publication-title: Cell doi: 10.1016/S0092-8674(03)00194-6 – volume: 112 start-page: 831 year: 2003 ident: 2019111723410492300_B124 article-title: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. publication-title: Cell doi: 10.1016/S0092-8674(03)00190-9 – volume: 7 start-page: 129 year: 2005 ident: 2019111723410492300_B115 article-title: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. publication-title: Cancer Cell doi: 10.1016/j.ccr.2005.01.007 – volume: 18 start-page: 4754 year: 1999 ident: 2019111723410492300_B30 article-title: STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. publication-title: EMBO J doi: 10.1093/emboj/18.17.4754 – volume: 5 start-page: 33 year: 2004 ident: 2019111723410492300_B12 article-title: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm1280 – volume: 110 start-page: 4005 year: 2007 ident: 2019111723410492300_B123 article-title: Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. publication-title: Blood doi: 10.1182/blood-2007-03-080838 – volume: 4 start-page: 75 year: 2003 ident: 2019111723410492300_B113 article-title: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. publication-title: Lancet Oncol doi: 10.1016/S1470-2045(03)00979-3 – volume: 18 start-page: 1321 year: 2004 ident: 2019111723410492300_B108 article-title: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. publication-title: Leukemia doi: 10.1038/sj.leu.2403426 – volume: 20 start-page: 1767 year: 2006 ident: 2019111723410492300_B132 article-title: Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. publication-title: Leukemia doi: 10.1038/sj.leu.2404318 – volume: 1072 start-page: 129 year: 1991 ident: 2019111723410492300_B41 article-title: The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. publication-title: Biochim Biophys Acta – volume: 12 start-page: 467 year: 2007 ident: 2019111723410492300_B37 article-title: Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. publication-title: Cancer Cell doi: 10.1016/j.ccr.2007.10.015 – volume: 111 start-page: 2904 year: 2008 ident: 2019111723410492300_B53 article-title: BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia. publication-title: Blood doi: 10.1182/blood-2007-05-091769 – volume: 108 start-page: 319 year: 2006 ident: 2019111723410492300_B69 article-title: BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. publication-title: Blood doi: 10.1182/blood-2005-07-2815 – volume: 274 start-page: 27956 year: 1999 ident: 2019111723410492300_B14 article-title: Activation of the Abl tyrosine kinase in vivo by Src homology 3 domains from the Src homology 2/Src homology 3 adaptor Nck. publication-title: J Biol Chem doi: 10.1074/jbc.274.39.27956 – volume: 349 start-page: 2483 year: 2003 ident: 2019111723410492300_B96 article-title: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. publication-title: N Engl J Med doi: 10.1056/NEJMoa030847 – volume: 9 start-page: 117 year: 2002 ident: 2019111723410492300_B22 article-title: Structure of the Bcr-Abl oncoprotein oligomerization domain. publication-title: Nat Struct Biol – volume: 96 start-page: 2269 year: 2000 ident: 2019111723410492300_B34 article-title: Bcr/Abl activates transcription of the Bcl-X gene through STAT5. publication-title: Blood doi: 10.1182/blood.V96.6.2269 – volume: 279 start-page: 34227 year: 2004 ident: 2019111723410492300_B50 article-title: A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. publication-title: J Biol Chem doi: 10.1074/jbc.M402290200 – volume: 2 start-page: 117 year: 2002 ident: 2019111723410492300_B109 article-title: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. publication-title: Cancer Cell doi: 10.1016/S1535-6108(02)00096-X – volume: 283 start-page: 18292 year: 2008 ident: 2019111723410492300_B117 article-title: Solution conformations and dynamics of Abl kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. publication-title: J Biol Chem doi: 10.1074/jbc.M801337200 – volume: 51 start-page: 3048 year: 1991 ident: 2019111723410492300_B45 article-title: Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. publication-title: Cancer Res – volume: 12 start-page: 1181 year: 2006 ident: 2019111723410492300_B101 article-title: Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. publication-title: Nat Med doi: 10.1038/nm1487 – volume: 354 start-page: 2542 year: 2006 ident: 2019111723410492300_B119 article-title: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. publication-title: N Engl J Med doi: 10.1056/NEJMoa055104 – volume: 5 start-page: 243 year: 2006 ident: 2019111723410492300_B68 article-title: BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. publication-title: DNA Repair doi: 10.1016/j.dnarep.2005.10.005 – volume: 103 start-page: 2794 year: 2006 ident: 2019111723410492300_B89 article-title: Gene expression changes associated with progression and response in chronic myeloid leukemia. publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0510423103 – volume: 4 start-page: e144 year: 2006 ident: 2019111723410492300_B20 article-title: A Src-like inactive conformation in the abl tyrosine kinase domain. publication-title: PLoS Biol doi: 10.1371/journal.pbio.0040144 – volume: 18 start-page: 2676 year: 1999 ident: 2019111723410492300_B70 article-title: Mutator phenotype of BCR–ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. publication-title: Oncogene doi: 10.1038/sj.onc.1202619 – volume: 18 start-page: 671 year: 2004 ident: 2019111723410492300_B71 article-title: Clonal evolution in chronic myelogenous leukemia. publication-title: Hematol Oncol Clin North Am doi: 10.1016/j.hoc.2004.03.012 – volume: 8 start-page: 355 year: 2005 ident: 2019111723410492300_B82 article-title: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. publication-title: Cancer Cell doi: 10.1016/j.ccr.2005.10.015 – volume: 62 start-page: 4236 year: 2002 ident: 2019111723410492300_B118 article-title: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). publication-title: Cancer Res – volume: 105 start-page: 2640 year: 2005 ident: 2019111723410492300_B128 article-title: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. publication-title: Blood doi: 10.1182/blood-2004-08-3097 – volume: 88 start-page: 2410 year: 1996 ident: 2019111723410492300_B11 article-title: Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). publication-title: Blood doi: 10.1182/blood.V88.7.2410.bloodjournal8872410 – volume: 7 start-page: 441 year: 2007 ident: 2019111723410492300_B67 article-title: Chronic myeloid leukaemia as a model of disease evolution in human cancer. publication-title: Nat Rev Cancer doi: 10.1038/nrc2147 – volume: 99 start-page: 680 year: 2007 ident: 2019111723410492300_B106 article-title: Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djk150 – volume: 12 start-page: 27 year: 2003 ident: 2019111723410492300_B23 article-title: Autoinhibition of Bcr-Abl through its SH3 domain. publication-title: Mol Cell doi: 10.1016/S1097-2765(03)00274-0 – volume: 349 start-page: 1399 year: 2003 ident: 2019111723410492300_B111 article-title: Minimal residual disease in chronic myeloid leukemia. publication-title: N Engl J Med doi: 10.1056/NEJMp038130 – volume: 16 start-page: 335 year: 1998 ident: 2019111723410492300_B47 article-title: BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. publication-title: Oncogene doi: 10.1038/sj.onc.1201490 – volume: 453 start-page: 110 year: 2008 ident: 2019111723410492300_B61 article-title: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. publication-title: Nature doi: 10.1038/nature06866 – volume: 107 start-page: 4898 year: 2006 ident: 2019111723410492300_B32 article-title: Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. publication-title: Blood doi: 10.1182/blood-2005-09-3596 – volume: 351 start-page: 657 year: 2004 ident: 2019111723410492300_B48 article-title: Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. publication-title: N Engl J Med doi: 10.1056/NEJMoa040258 – volume: 65 start-page: 4500 year: 2005 ident: 2019111723410492300_B127 article-title: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-0259 – volume: 110 start-page: 2578 year: 2007 ident: 2019111723410492300_B97 article-title: Leukemia stem cells in a genetically defined murine model of blast-crisis CML. publication-title: Blood doi: 10.1182/blood-2007-02-073031 – volume: 21 start-page: 2283 year: 2007 ident: 2019111723410492300_B79 article-title: Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. publication-title: Genes Dev doi: 10.1101/gad.1588607 – volume: 108 start-page: 2811 year: 2006 ident: 2019111723410492300_B77 article-title: Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. publication-title: Blood doi: 10.1182/blood-2006-04-017400 – volume: 13 start-page: 2341 year: 1994 ident: 2019111723410492300_B13 article-title: c-Abl kinase regulates the protein binding activity of c-Crk. publication-title: EMBO J doi: 10.1002/j.1460-2075.1994.tb06518.x – volume: 293 start-page: 876 year: 2001 ident: 2019111723410492300_B110 article-title: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. publication-title: Science doi: 10.1126/science.1062538 – volume: 103 start-page: 4010 year: 2004 ident: 2019111723410492300_B73 article-title: The biology of CML blast crisis. publication-title: Blood doi: 10.1182/blood-2003-12-4111 – volume: 92 start-page: 3829 year: 1998 ident: 2019111723410492300_B7 article-title: Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. publication-title: Blood doi: 10.1182/blood.V92.10.3829 – volume: 344 start-page: 1038 year: 2001 ident: 2019111723410492300_B2 article-title: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. publication-title: N Engl J Med doi: 10.1056/NEJM200104053441402 – volume: 24 start-page: 6432 year: 2005 ident: 2019111723410492300_B46 article-title: Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. publication-title: Oncogene doi: 10.1038/sj.onc.1208796 – volume: 117 start-page: 2562 year: 2007 ident: 2019111723410492300_B137 article-title: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. publication-title: J Clin Invest doi: 10.1172/JCI30890 – volume: 23 start-page: 681 year: 2003 ident: 2019111723410492300_B86 article-title: Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. publication-title: Int J Oncol – volume: 354 start-page: 2531 year: 2006 ident: 2019111723410492300_B120 article-title: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. publication-title: N Engl J Med doi: 10.1056/NEJMoa055229 – volume: 190 start-page: 411 year: 1999 ident: 2019111723410492300_B33 article-title: Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. publication-title: J Exp Med doi: 10.1084/jem.190.3.411 |
| SSID | ssj0014325 |
| Score | 2.5017002 |
| SecondaryResourceType | review_article |
| Snippet | Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene.... Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique molecular event, the BCR-ABL1 oncogene.... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1619 |
| SubjectTerms | Animals Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Gene Expression Regulation, Leukemic - physiology Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology Molecular Biology Review Signal Transduction - physiology |
| Title | Molecular biology of bcr-abl1–positive chronic myeloid leukemia |
| URI | https://dx.doi.org/10.1182/blood-2008-03-144790 https://www.ncbi.nlm.nih.gov/pubmed/18827185 https://www.proquest.com/docview/66936915 https://pubmed.ncbi.nlm.nih.gov/PMC3952549 |
| Volume | 113 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLVgEI8Ngg6P8swCsakMjh3nsSwVaAQqEmJGml3kOLamIk1QJ0UaVvwDf8iXcB3baTMUDcwmivJ0ck6ce32v70HoRRHqtIi0wIrxCEciJjgTTGJNMl0WUaTCTmxi_jE-OIreH_Njr3fvZpe0xSv5fee8ksugCtsAVzNL9j-Q7S8KG2Ad8IUlIAzLf8J47rVtJ76WEph-hVxhUVShT2NgNi_rm5pIWwh3sjxTVbMoJ5Vaf1HLhRgEdiunHm9HQxd124XSw1M8Ay6JpR2GrTQ8UtPHL0zCrosnrFxukR9IyEzu8VZ31c9wGSRgmt-ZUaGz-CvXSZqq1oSSQS9qp5Q6uqRbfSLYlNnW_xUMQLK7705NLVibr2-zMhgGdy-xcqLnqmJ_7owpaBcl0EWCWXUVXaPgKRgRiw-fNoGkiFErYuEew82ehHu93nWnv1knf3of55Not6ySwzvotnMngqnlxl10RdUjtD-tRdssz4KXQZfg21FjhK6_8Ws3Z17mb4RuzF12xT6a9nwKHJ-CRgeeT79-_PRMChyTAsekwDPpHjp69_ZwdoCdxAaWnCYtpoIksuTmPWZpSU2xNqoLnoisLKnSLI5kLGWUqkxIrpmKKBFGs6zgsYp1GrP7aK9uavUQBarMuAxLqTnXUQaOtyRFLHRJRMZLRtIxYv7V5tLVnzcyKFXe-aEpzTtAnC4qyy0gY4T7s77a-isXHJ941HJnQ1rbMAeaXXDmcw9yDhCYuJmoVbM-zePYqF6GfIweWMg3LQH_FIw72JMMyNAfYIq3D_fUi5OuiDvLuBmbeXTp9j5GtzZf8RO0167W6ikYyG3xrPsEfgNo3Lef |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+biology+of+bcr-abl1%E2%80%93positive+chronic+myeloid+leukemia&rft.jtitle=Blood&rft.au=Quint%C3%A1s-Cardama%2C+Alfonso&rft.au=Cortes%2C+Jorge&rft.date=2009-02-19&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=113&rft.issue=8&rft.spage=1619&rft.epage=1630&rft_id=info:doi/10.1182%2Fblood-2008-03-144790&rft.externalDocID=S0006497120376643 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |